Navigation Links
Bacterin International Introduces OsteoSelect(R) DBM Putty
Date:3/10/2010

BELGRADE, Mont., March 10 /PRNewswire/ -- Bacterin International, Inc. (Bacterin), a biologic company focused on the development of innovative, specialty allografts, announces the introduction of OsteoSelect® DBM Putty for orthopedic bone grafting applications.  OsteoSelect® is a moldable allograft designed to withstand irrigation while exhibiting osteoinductive properties for improved bone regeneration.  OsteoSelect® will be an ideal complement to Bacterin's current product portfolio, which focuses on optimizing handling characteristics and biologic performance of grafting materials for surgeons.

"The development and release of Bacterin's first allograft based medical device represents another significant milestone in the evolution of Bacterin's Biologics Division," said Gregory Juda, PhD, Senior Biologics Scientist for Bacterin and product manager of OsteoSelect® DBM Putty.  Dr. Juda continued to say, "Bacterin used considerable input from the surgical community during the design of OsteoSelect® DBM Putty and thus far, the feedback from orthopedic end users has been overwhelmingly positive.  It was Bacterin's goal to bring to the market a bone graft substitute that offers the surgeon excellent handling properties and device level sterility without compromising the biologic performance of the material.  We have achieved that goal."

OsteoSelect® DBM Putty is a malleable bone grafting material comprised of demineralized bone matrix allograft suspended in a polymer carrier material.  The product was engineered using feedback from key surgeons in several orthopedic specialties, with a focus on providing solutions to the shortcomings noted with other commercially available DBM products.  The osteoinductive potential of every lot of terminally sterilized OsteoSelect® is evaluated in an animal model prior to release thus providing surgeons with a bone grafting solution that is both safe and biologically active.  Bacterin licensed the proprietary carrier technology from Osteotech Inc., and funding provided by a grant from the Montana Board of Research and Commercialization Technology was essential to the concept development and preclinical studies of the OsteoSelect® product.

OsteoSelect® DBM Putty will be commercially launched at the American Academy of Orthopaedic Surgeons in New Orleans, Louisiana, March 10-12.

Bacterin develops innovative products designed to enhance surgical capabilities and improve patient outcomes. Bacterin Biologics is a recognized leader in biomaterial design and musculoskeletal reconstruction. Bacterin's proprietary biologic scaffolds include OsteoSponge®, OsteoWrap®,  OsteoLock®, and BacFast®.  Bacterin's Devices Division is committed to the development of bioactive coating technologies for medical devices.

Certain matters discussed in this press release are forward-looking statements with regards to the Company's future plans, objectives, and anticipated performance.  These forward-looking statements can generally be identified as such because the context of the statement will include words, such as Bacterin International, Inc. "expects," "should," "believes," "anticipates" or words of similar import. Bacterin International, Inc. believes the expectations reflected in any forward-looking statements are based on reasonable assumptions; the Company cannot give any assurance that the expectations will be attained.  These forward-looking statements are only made as of the date of this press release; Bacterin International, Inc. undertakes no obligation to publicly update this information.

For more information regarding Bacterin, or this press release, please visit www.bacterin.com.  

SOURCE Bacterin International, Inc.

Back to top

RELATED LINKS
http://www.bacterin.com

'/>"/>

SOURCE Bacterin International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Bacterin International Completes $3 Million Private Placement
2. International Growth Continues: Rhythmlink International, LLC Receives CE Marking & ISO 13485 Certification
3. Concentric Medical and the Merci Retrieval System(R) Highlighted at the 2010 International Stroke Conference
4. Max Neeman International and AMEDON Collaborate to Increase EDC Performance
5. International Merchant Advisors Reaches Agreement in Principal to Acquire First Medical Marijuana Clinic Operations
6. Biomedical Advanced Research and Development Authority (BARDA) Project for Radiation Exposure Research Awarded to SRI International
7. Microfluidics International Corporation Announces Fourth Quarter and Year-End 2009 Financial Results
8. PRA International Hosts a Late Phase Services Webinar Establishing Value for Diagnostics & Biomarkers in a Real-Life Setting
9. Microfluidics International Corporation to Report Fourth Quarter and Year-end 2009 Financial Results on February 23, 2010
10. Cancer Expert Dr. Eric Rowinsky to Oversee Oncology Product Development at RRD International
11. International Merchant Advisors, Inc. Signs LOI to Invest in Pharmaceutical Chain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... Feb. 9, 2016 On Tuesday, ... (FDA) met with its Arthritis Advisory Committee ... of Johnson & Johnson,s Remicade and most ... in the U.S. The Biologics Prescribers Collaborative ... - Alliance for Patient Access, American Association ...
(Date:2/10/2016)... 2016 Demonstrates changes in ... receptor selectivity   1 receptor ... entered clinical development as a new treatment for ...   --> 1 receptor agonist, ... clinical development as a new treatment for cognitive ...
(Date:2/9/2016)... Corporation (NASDAQ: PODD ) (Insulet or the Company), the ... OmniPod ® Insulin Management System, today announced ... Insulet,s Board of Directors. With his appointment, the Board is ... --> --> Mr. Lemoine ... a deep knowledge of accounting, financial reporting and internal controls ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... 2016 , ... The Wickman Agency in Garland, TX has ... community. Pledging to select a new beneficiary every 60 days, the agency will ... is to bring community awareness to important local causes by forming campaigns which ...
(Date:2/10/2016)... ... February 10, 2016 , ... Dr. Peyman Ghasri, skin ... a variety of comprehensive procedures for facial enhancement. The treatments now available at ... enhancement and nasal reshaping. , As a result, patients can improve virtually ...
(Date:2/10/2016)... ... February 10, 2016 , ... Intalere’s ... together more than 200 of the country’s top healthcare executives to share insights ... true benefit of the Forum is the provider-centric perspective, experience, expertise and strategy ...
(Date:2/10/2016)... ... ... AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the peripheral ... December 31, 2015 on Monday, February 29, 2016 after the market closes. , The ... release at 4:30 PM ET. Investors interested in participating by phone are invited to ...
(Date:2/10/2016)... ... February 10, 2016 , ... Pediatric therapists ... their patients. Research shows that the Goal Attainment Scale (GAS) captures 20% more ... challenge and learn more about the Goal Attainment Scale, Education Resources Inc. is ...
Breaking Medicine News(10 mins):